Loading
Sunshine Lake Pharma (HEC)
Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer.
Also called: Sunshine Lake Pharma Co., Ltd.HEC Pharm
Overview
Sunshine Lake Pharma, part of the HEC (Dongyangguang) group in Dongguan, Guangdong, is a Chinese pharmaceutical company with antiviral, metabolic and oncology pipelines. In cancer it is developing clifutinib, a small-molecule FLT3 inhibitor in a phase 3 trial for FLT3-mutated acute myeloid leukaemia, and lerotinib, a small-molecule kinase inhibitor in a phase 3 trial for oesophageal cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the group website.
Headquarters
Dongguan, CN
Scorecard
All companies#356of 1245 companies, score 11
- phase 3 +6
- modalities +2
- registry trials +3
0 approved, 2 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Products
2Phase 3small molecule
Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.
Connected
9Similar pages
cancers
fronts
drugs
Phase 3small molecule
Phase 3small molecule (structure undisclosed or not yet in PubChem)
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
hec.cn · 1
A source that has moved or gone is reported by the weekly link check. /audit/